UM  > Faculty of Health Sciences
Residential Collegefalse
Status已發表Published
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment
Platz E.A.3; Yegnasubramanian S.1; Liu J.O.1; Chong C.R.1; Shim J.S.1; Kenfield S.A.2; Stampfer M.J.2; Willett W.C.2; Giovannucci E.2; Nelson W.G.1
2011-06-01
Source PublicationCancer Discovery
ISSN21598274 21598290
Volume1Issue:1Pages:68-77
Abstract

Identification of novel indications for commonly prescribed drugs could accelerate translation of therapies. We investigated whether any clinically used drugs might be useful in treating prostate cancer by coupling an efficient, high-throughput laboratory- based screen and a large prospective cohort study. In stage one, we conducted an in vitro prostate cancer cell cytotoxicity screen of 3,187 compounds. Digoxin emerged as the leading candidate, given its potency in inhibiting proliferation in vitro (the concentration of the drug at which proliferation was inhibited by 50%: mean of 163 nM) and its common use. In stage two, we evaluated the association between the leading candidate drug from stage one and prostate cancer risk in 47,884 men followed up from 1986 through 2006. Regular digoxin users [vs nonusers: relative risk (RR) = 0.76; 95% confidence interval (CI), 0.61-0.95], especially users for ≥10 years (RR = 0.54; 95% CI, 0.37-0.79; P trend < 0.001), had a lower prostate cancer risk. Digoxin was highly potent in inhibiting prostate cancer cell growth in vitro, and its use was associated with a 25% lower prostate cancer risk. siGnificance: Our two-stage transdisciplinary approach for drug repositioning provides compelling justification for further mechanistic and possibly clinical testing of the leading nonchemotherapy candidate, digoxin, a cardiac glycoside, as a drug for prostate cancer treatment. Perhaps of equal importance, our study illustrates the power of the transdisciplinary approach in translational cancer research. By coupling laboratory and epidemiologic methods and thinking, we reduced the probability of identifying false-positive candidate drugs for the next steps in testing. © 2011 American Association for Cancer Research.

DOI10.1158/2159-8274.CD-10-0020
URLView the original
Indexed BySCIE
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000295780300023
Scopus ID2-s2.0-79959922456
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Johns Hopkins Medical Institutions
2.Brigham and Women's Hospital
3.Johns Hopkins Bloomberg School of Public Health
Recommended Citation
GB/T 7714
Platz E.A.,Yegnasubramanian S.,Liu J.O.,et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment[J]. Cancer Discovery, 2011, 1(1), 68-77.
APA Platz E.A.., Yegnasubramanian S.., Liu J.O.., Chong C.R.., Shim J.S.., Kenfield S.A.., Stampfer M.J.., Willett W.C.., Giovannucci E.., & Nelson W.G. (2011). A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discovery, 1(1), 68-77.
MLA Platz E.A.,et al."A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment".Cancer Discovery 1.1(2011):68-77.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Platz E.A.]'s Articles
[Yegnasubramanian S.]'s Articles
[Liu J.O.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Platz E.A.]'s Articles
[Yegnasubramanian S.]'s Articles
[Liu J.O.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Platz E.A.]'s Articles
[Yegnasubramanian S.]'s Articles
[Liu J.O.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.